186 related articles for article (PubMed ID: 34187942)
1. Celebrating the 80th anniversary of hormone ablation for prostate cancer.
Zoubeidi A; Ghosh PM
Endocr Relat Cancer; 2021 Jul; 28(8):T1-T10. PubMed ID: 34187942
[TBL] [Abstract][Full Text] [Related]
2. Antiandrogens in prostate cancer endocrine therapy.
Culig Z; Bartsch G; Hobisch A
Curr Cancer Drug Targets; 2004 Aug; 4(5):455-61. PubMed ID: 15320720
[TBL] [Abstract][Full Text] [Related]
3. Androgen axis in prostate cancer.
Culig Z; Bartsch G
J Cell Biochem; 2006 Oct; 99(2):373-81. PubMed ID: 16598769
[TBL] [Abstract][Full Text] [Related]
4. Novel hormonal approaches in prostate cancer.
Friedlander TW; Ryan CJ
Curr Oncol Rep; 2009 May; 11(3):227-34. PubMed ID: 19336015
[TBL] [Abstract][Full Text] [Related]
5. Targeted androgen pathway suppression in localized prostate cancer: a pilot study.
Mostaghel EA; Nelson PS; Lange P; Lin DW; Taplin ME; Balk S; Ellis W; Kantoff P; Marck B; Tamae D; Matsumoto AM; True LD; Vessella R; Penning T; Hunter Merrill R; Gulati R; Montgomery B
J Clin Oncol; 2014 Jan; 32(3):229-37. PubMed ID: 24323034
[TBL] [Abstract][Full Text] [Related]
6. Androgens in prostate cancer: A tale that never ends.
Hou Z; Huang S; Li Z
Cancer Lett; 2021 Sep; 516():1-12. PubMed ID: 34052327
[TBL] [Abstract][Full Text] [Related]
7. Androgen action in the prostate gland.
Yadav N; Heemers HV
Minerva Urol Nefrol; 2012 Mar; 64(1):35-49. PubMed ID: 22402316
[TBL] [Abstract][Full Text] [Related]
8. Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer.
Knudsen KE; Scher HI
Clin Cancer Res; 2009 Aug; 15(15):4792-8. PubMed ID: 19638458
[TBL] [Abstract][Full Text] [Related]
9. Management of hormone-sensitive metastatic prostate cancer.
Agarwal N; Hussain M
Hematol Oncol Clin North Am; 2013 Dec; 27(6):1221-41, viii. PubMed ID: 24188260
[TBL] [Abstract][Full Text] [Related]
10. Endocrine/paracrine/autocrine survival factor activity of bone microenvironment participates in the development of androgen ablation and chemotherapy refractoriness of prostate cancer metastasis in skeleton.
Bogdanos J; Karamanolakis D; Tenta R; Tsintavis A; Milathianakis C; Mitsiades C; Koutsilieris M
Endocr Relat Cancer; 2003 Jun; 10(2):279-89. PubMed ID: 12790789
[TBL] [Abstract][Full Text] [Related]
11. Combination Therapy with Androgen Receptor Pathway Inhibitors for Prostate Cancer.
Blas L; Shiota M
Curr Cancer Drug Targets; 2023; 23(6):428-432. PubMed ID: 36803751
[No Abstract] [Full Text] [Related]
12. A new prostate cancer therapeutic approach: combination of androgen ablation with COX-2 inhibitor.
Cai Y; Lee YF; Li G; Liu S; Bao BY; Huang J; Hsu CL; Chang C
Int J Cancer; 2008 Jul; 123(1):195-201. PubMed ID: 18386814
[TBL] [Abstract][Full Text] [Related]
13. Hormone treatment for prostate cancer: current issues and future directions.
Ichikawa T; Suzuki H; Ueda T; Komiya A; Imamoto T; Kojima S
Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():58-63. PubMed ID: 16273367
[TBL] [Abstract][Full Text] [Related]
14. Androgen receptor mutations in carcinoma of the prostate: significance for endocrine therapy.
Culig Z; Klocker H; Bartsch G; Hobisch A
Am J Pharmacogenomics; 2001; 1(4):241-9. PubMed ID: 12083956
[TBL] [Abstract][Full Text] [Related]
15. Molecular biology and cellular physiology of refractoriness to androgen ablation therapy in advanced prostate cancer.
Mitsiades CS; Koutsilieris M
Expert Opin Investig Drugs; 2001 Jun; 10(6):1099-115. PubMed ID: 11772238
[TBL] [Abstract][Full Text] [Related]
16. The androgen receptor in prostate cancer: therapy target in search of an integrated diagnostic test.
Ross JS
Adv Anat Pathol; 2007 Sep; 14(5):353-7. PubMed ID: 17717436
[TBL] [Abstract][Full Text] [Related]
17. The role of the androgen receptor in the development of prostatic hyperplasia and prostate cancer.
Chatterjee B
Mol Cell Biochem; 2003 Nov; 253(1-2):89-101. PubMed ID: 14619959
[TBL] [Abstract][Full Text] [Related]
18. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.
Vis AN; Schröder FH
BJU Int; 2009 Aug; 104(4):438-48. PubMed ID: 19558559
[TBL] [Abstract][Full Text] [Related]
19. A road map to comprehensive androgen receptor axis targeting for castration-resistant prostate cancer.
Mitsiades N
Cancer Res; 2013 Aug; 73(15):4599-605. PubMed ID: 23887973
[TBL] [Abstract][Full Text] [Related]
20. Androgen Control in Prostate Cancer.
Pelekanou V; Castanas E
J Cell Biochem; 2016 Oct; 117(10):2224-34. PubMed ID: 27104784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]